(Q30847612)

27 June 2017

p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol (English)

1 reference

27 June 2017

5

Jacques Pouysségur

1 reference

27 June 2017

4

Peter Schultz

1 reference

27 June 2017

3

Nathanael Gray

1 reference

27 June 2017

6

Laurent Meijer

1 reference

27 June 2017

Marie Knockaert

1

1 reference

27 June 2017

Philippe Lenormand

series ordinal

2

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

27 June 2017

1 reference

27 June 2017

21

1 reference

27 June 2017

42

1 reference

27 June 2017

6413-6424

1 reference

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles

27 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cell cycle regulation of p70 S6 kinase and p42/p44 mitogen-activated protein kinases in Swiss mouse 3T3 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

CDK inhibition and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Designing inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Interaction of oncodazole (R 17934), a new anti-tumoral drug, with rat brain tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cyclin-dependent kinase 2 nucleocytoplasmic translocation is regulated by extracellular regulated kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Characterization of novel inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cyclin-dependent kinase inhibitors: novel anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Chemical inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Functional expression and growth factor activation of an epitope-tagged p44 mitogen-activated protein kinase, p44mapk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cyclin-dependent kinases: engines, clocks, and microprocessors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Development of anticancer drugs targeting the MAP kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Activation of the MKK/ERK pathway during somatic cell mitosis: direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

The design and synthesis of purine inhibitors of CDK2. III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Quinazolines as cyclin dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cyclin-dependent kinase inhibitors for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Dissociation of nuclear and cytoplasmic cell cycle progression by drugs employed in cell synchronization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Inhibition of cyclin-dependent kinases by purine analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Cyclin-Dependent Kinase Inhibition by New C-2 Alkynylated Purine Derivatives and Molecular Structure of a CDK2−Inhibitor Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

Identification of selective inhibitors of cyclin dependent kinase 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Activation of ternary complex factor Elk-1 by MAP kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Induction of apoptosis by the anti-tubulin drug colcemid: relationship of mitotic checkpoint control to the induction of apoptosis in HeLa S3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205908

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1205908

1 reference

Dimensions Publication ID

27 June 2017

0 references

1 reference